• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

xalkori - Articles and news items

approval-pfizer-lung-cancer

EU approval for Pfizer’s non-small cell lung cancer drug

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The drug exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC and met its primary endpoint of ORR. Tumours were tested for ROS1 rearrangements by laboratory-developed break-apart fluorescence in situ hybridization (FISH) (96%) or real-time polymerase chain reaction (RT-PCR) (4%) assay…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +